AG-120
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 291 patients (estimated)
- Sponsors
- Institut de Recherches Internationales Servier
- Tags
- Isocitrate Dehydrogenase 1 (IDH1) Inhibitor
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1365
- NCT Identifier
- NCT02074839
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.